Cite
HARVARD Citation
Llibre, J. et al. (2018). Efficacy, safety, and tolerability of dolutegravir-rilpivirine for the maintenance of virological suppression in adults with HIV-1: phase 3, randomised, non-inferiority SWORD-1 and SWORD-2 studies. Lancet. 391 (10123), pp. 839-849. [Online].